A Coincidence of HLA-B27 Negative Spondyloarthritis and Paravertebral Non-Hodgkin’s Lymphoma – A Lesson to be Learned from the Past Experience by Marija Glasnović et al.
219
M. Glasnović et al.: Spondyloarthritis and Paravertebral Non-Hodgkiǹ s Lymphoma, Coll. Antropol. 39 (2015) 1: 219–224
sis has been based on the radiographic signs of the SI 
joints infl ammatory affection4. This has been for years the 
reason of diagnostic delay, as radiographic signs refl ect 
structural changes, the consequences of infl ammation, 
rather than infl ammation itself5. Testing for Human Leu-
kocyte Antigen B27 (HLA-B27) has been shown to con-
tribute to the diagnosis in patients with symptoms of low 
back pain and the absence of radiographic signs of sacroi-
liitis, or when peripheral arthritis is dominating. The ra-
tional is that, in these patients, HLA-B27 positivity brings 
a 20-fold higher risk of SpA6. Diagnostic procedure has 
recently been improved by introducing magnetic reso-
nance imaging (MRI) technicque to detecting early in-
fl ammatory signs of sacroiliitis. In this regard, it has been 
observed that a reasonable proportion of patients with 
early MRI signs of the SI joints affection subsequently 
turn into radiographically recognised sacroiliitis7. Based 
Ankylosing spondyilitis (AS) is a chronic infl amma-
tory disease of the sacroiliac (SI) and vertebral joints 
which begins in early adulthood, affects men rather than 
women and leads to severe disability1. In addition to AS, 
four other entities have been included under the common 
clasiffi cation criteria of spondyloathritides (SpA), based 
on similar clinical and genetical features. They include: 
psoriatic arthritis, reactive arthritis, arthritis associated 
with infl ammatory bowel disease and undifferentiated 
arthritis2. These entities can also be divided according to 
whether peripheral or axial joints are predominantly af-
fected. The importance of the SpA concept is in observa-
tion that patients diagnosed with SpA can also progress 
into the overt spine disease.
The common symptom of all SpA subgroups is infl am-
matory back pain, characterized with morning stiffness 
and nocturnal lower back and buttock pain3. Yet, diagno-
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A B S T R A C T
We reported a case of a 71-year-old woman with progressive low back pain and neurologic symptoms of lower ex-
tremities, who in the background had the coexistence of spondyloarthritis (SpA) and non Hodgkin’s lymphoma of the 
paravertebral location. This example describes a situation where SpA with minimal sacroiliac joints affection has nev-
ertheless led to the overt axial SpA. This situation included undifferentiated or reactive SpA, as well as unusual disease 
context, presented with late-life disease onset, older age, female gender and no obvious hereditary predisposition. This 
combination of comorbid factors could allow environmental and disease-specifi c factors to accumulate over time and to, 
by modifying the primary, low-penetrant genetic background, lead to the development of lymphoma. By achieving better 
understanding of disease pathophysiology dynamic, we will be able to improve our capabilities to navigate biologic 
therapy in the future, in order to prevent the development of both, overt SpA and lymphoproliferative disease.
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on this observation, MRI testing is now involved in a new, 
more accurate classifi cation of SpA8. In this classifi cation, 
combination of clinical, imaging and laboratory parame-
ters is used to improve decision on diagnosis, which is 
particularly helpful in early disease stages, when radio-
graphic signs of disease are still absent.
The need for more accurate identifi cation of patients 
with SpA and especially of those of them who have higher 
disease activity and are therefore at increased risk of de-
veloping severe disease, has been emhasized in the recent 
years, when new anti-infl amatory drugs have been shown 
to provide substantial benefi t to these patients1,9,10. Al-
though generally benefi cial, these drugs can also lead to 
harm11. This is a reason more why it is important to un-
derstand the pathogenetic background of this group of 
diseases, where the level of infl ammation and therefore 
also anti-infl ammatory drugs, can change their course.
Evidence has been increasing to support the associa-
tion of infl ammatory rheumatic diseases with other seri-
ous conditions, including cardiovascular diseases, cancer 
and lymphoprolipherative diseases12–14. Learning from 
case reports is an appropriate method to improve our sen-
sibility on the existence of a variety of these conditions and 
to provide us with better insight into their complex under-
lying pathophysiologic network. In this way also, this 
method can improve our capabilities to cope with chal-
lenges of biological treatment.
In this sense, a case report presented here is of utmost 
importance. It should turn our attention on situations 
where SpA with minimal SI joints affection can neverthe-
less lead to overt axial SpA. These situations may include, 
as presented here, cases with undifferentiated or reactive 
SpA and less usual context, such as late-life disease onset 
in a woman with no obvious hereditary predisposition. 
Such specifi c situation, probably exactly for the reason of 
a delay in clinical expression of SpA, or of a slow course of 
disease progression, could lead to the development of an-
other serious disorder, in the form of non Hodgkin’s lym-
phoma (NHL). In this way, this report tends to emphasize 
the importance of the context, in our efforts to predict 
future events. This is also the fi rst case reported until 
now, within those engaged in SpA matters, presented with 
paravertebral location of NHL.
Case Report
A 71-year-old woman was referred to the rheumatolo-
gist in March, 2013, for severe low back pain with irra-
diation into the left low extremity. The pain has started 3 
months ago and has been becoming worse, despite the use 
of analgesics and nonsteroidal anti-infl ammatory drugs 
and physical therapy. Since several days ago, the pain has 
become penetrating and she felt numbness in both legs. 
Laboratory check up indicated mild anaemia, with red 
blood cell (RBC) count of 3.95 (x 1012/L) and Haemoglobin 
(Hb) level of 116 g/L. Infl ammatory markers were not in 
favour of acute infl ammation, with sedimentation rate 
(SE) of 21, the White Blood Cell (WBC) count of 4.9 (103/
mm3) and C-reactive protein (CRP) of 1.9 (mg/L).
This was her second visit to the rheumatologist. The 
fi rst one took place 7 years ago (2006), when she also pre-
sented with low back pain and lumboischialgia. On the 
available radiographs from that time, overt degenerative 
changes of the cervical and thoracic spine were evident, 
including large osteophytes and syndesmophytes. Local 
fusion of thoracic vertrebae was suspected on »bamboo 
spine«. Laboratory testing, at that fi rst encounter, did not 
show active infl ammation. HLA-B27 antigen testing yield-
ed a negative result.
At this repeated visit, she has been hospitalized for 
further examination. Medical hystory did not reveal rheu-
matic diseases in the family and she denied peripheral 
joints swelling from before. She has only had hypertension 
for a long time. Her sister died from myocardial infarction. 
When she was 59, she experienced an episode of post 
menopausal vaginal bleeding. On examination, she still 
looked overweight, although noted the lost of 20 kg in the 
last 4 months. When questionned, she reported on low 
back morning stiffness of 2h duration and the pain in the 
knees, more intensively expressed on the left-side. There 
were no eczematous rash or sole lesions on the skin. Pe-
ripheral lymph nodes did not seem enlarged, nor the liver 
and spleen. Neither ultrasound abdominal examination 
could provide us with such information. All tests done, 
including blood biochemical tests, rheumatoid factors test-
ing, urine microbiology culture and monoclonal proteins 
in the blood, were within the reference range. Only cervi-
cal and urethral smear culture was positive on ureaplas-
ma urealyticum. Renewed radiography of the thoracic and 
lumbar spine demonstrated paravertebral ossifi cation and 
fl owing osteophytes accross multiple vertebral levels, on 
the ventral and lateral sides, predominantly in the tho-
racic spine (Figure 1 a,b). Degenerative intervertebral 
osteochondrosis was visible alongside the thoracolumbar 
spine. Medial and dorsal columns were also degenera-
tively affected. The parrot’s beak osteophyte-like growths 
discriminated in favour of AS, or reactive SpA. In the 
same sense, the radiographs of the SI joints revealed ad-
vanced sacroiliitis, although of a minimal change involve-
ment, as based on patchy bilateral subhondral sclerosis 
and a small sclerotic area (insula compacta), located in the 
upper part of masse lateralis, on the right side.
Soon after admission, weakness in her legs increased, 
being suggestive of a spinal cord disease. There were no 
alerts in laboratory fi ndings, only midly increased total 
leukocyte count of 12.2. Urgent MRI scan of the spine, 
both native and contrast-enhanced, showed tissue/fl uid 
dorsal paravertebral mass in the close proximity of the 
thoracic aorta, with the spread in the caudal third of the 
thoracic spine, encompassing levels Th VII /VIII to L I/II 
(Figure 2). Described mass caused infi ltration and de-
struction of Th VII and Th IX vertebrae, while vertebrae 
Th X showed changed signals intensity by means of in-
fl ammation. There was infi ltration of this tumorous mass 
into canalis vertebralis at the level Th VIII – IX. Hetero-
geneity of MRI signals at the sagittal plane suggested also 
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spinal cord infi ltration, while its compression was clearly 
visible at the corresponding intervertebral (i.v.) disc space 
levels. Of other important MRI signs, there were overt 
degenerative changes of i.v. discs visible accross multiple 
levels of thoracolumbar spine and foraminal disc protru-
sions at all levels of lumbar spine. Liggmenta fl ava showed 
hypertrophy and there were also degenerative changes of 
small joints.
It was a month after admission, in the mid of April, 
when the patient was urgently replaced to the department 
of neurosurgery, for urgent spinal cord decompression and 
tumor mass pathological examination. Pathohistological 
and phenotypic analysis revealed Diffuse Large B-cell 
CD20+ Lymphoma (Figure 3). After surgery, the patient 
was replaced to the department of haemathology, for dis-
ease staging and polychemotherapy. Extensive staging 
showed the systemic spread of disease. Treatment, accord-
ing to the R-CHOP protocol, together with intrathecal 
Fig. 1. a, b. Radiographs of the thoracolumbal spine demonstrat-
ing paravertebral ossifi cation (a), and fl owing osteophytes on the 
ventral and lateral sides (b).
Fig. 3. a) Histological examination. The tumor tissue is densely 
populated by atipical cells with eosinophilic cytoplasm and erose 
boundar ies. The cells show oval pleomorphic hyperchromatic 
nuclei while large eosinophilic nucleoli are scattered all around. 
Mitotic activity is sporadic. The tumor tissue is highly saturated 
with vasculature abundatly infi ltrated with mononuclear infl la-
matory cells. (1000 x 1); b) Immunophenotypical analysis. Cells 
are strongly positive for B cell marker CD20. (400 x 1 c).
Fig. 2. Contrast-enhanced MRI scan of the spine showing tissue/
fl uid dorsal paravertebral mass with the spread in the caudal 
third of the thoracic spine and the thoracolumbal transition. De-
struction of Th VII and Th IX vertebrae and infi ltration of the 
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MTX application and local radioation, has immidiately 
been introduced. The requirement for the treatment with 
Rituximab was applied to the Hospital Drug Approval 
Committee. However, shortly after the beginning of the 
therapy, the clinical course of disease was complicated 
with severe neutropenia and mucositis. During the second 
cycle of the protocol, performed in June, Filgrastin was 
given to her through fi ve days, but very low leukocyte 
number has persisted and her physical condition has fur-
ther deteriorated. Three days after the last discharge, in 
August, she was urgently readmitted because of febrile 
neutropenia. She was also highly anemic. She had haemo-
culture positive for MRSA and an infl ammatory infi ltrate 
in the lungs. Ten days later, she died.
Discussion
Great advances in classifi cation of the SpA disease 
group and in assessment of disease activity, in the last 
decade, have allowed for clinical studies to be conducted 
in early disease state and the results of biological treat-
ment to be followed and compared1,15. Under the infl uence 
of targeted antiinfl ammatory therapy, such as anti-TNFa, 
it is likely that the biological landscape of these diseases 
turns on the change, by means of symptoms reduction and 
overt clinical disease disappearance15. In addition, the 
course of many comorbid conditions is also likely to be 
modifi ed. In this regard, it is known that, specifi cally for 
undifferentiated arthritis, dispersion of pathogenesis is 
possible, by gaining into the course of SpA also psoriasis 
or IBD16. Related to the latter, there may be a new onset 
of IBD, or an outbreak of silent colitis, arised from sub-
clinical gut infl ammation17. Or, SpA may occur after an 
asymptomatic gastrointestinal and urinary triggering 
infection, for which reason is diffi cult to discriminate be-
tween reactive and undifferentiated SpA, especially when 
peripheral disease is dominating16. Relative relationships 
between these patogenetic conditions and their transla-
tions over time, from one state to the other, can be larger-
ly affected by the use of biological treatment. To under-
stand these translations, it is important to get better 
insight into underlying complexity and the time-depen-
dent course of these conditions.
In this report, we presented an older woman with pro-
gressive low back pain and neurologic defi cit of the lower 
extremities who in the background had the coexistence of 
SpA and NHL of the paravertebral location. Although the 
link of systemic autoimmune and rheumatic diseases, 
such as Sjogren’s syndrome and rheumatoid arthritis 
(RA), with lymphoproliferative disorders, has already 
been established, this association in respect to SpA has 
not yet been confi rmed14,18,19. The probable reason is that 
this association is rare and might have been stayed beyond 
what observers can usually see. This problem has turned 
into the focus of researchers just recently, when it has been 
shown that anti-TNF-a therapy, applied in patients with 
RA, can trigger the development of lymphoma20. There 
have also been a few reports stating increased risk of lym-
phoma in patients with AS who have received anti-TNF 
treatment20,21.
Based on these reports, the question arises on the 
relative importance of infl ammation and immunosuppres-
sion in the pathogenesis of lymphoproliferative disorders. 
In this regard, the both, infl ammation-related and immu-
nodefi ciency-related etiologies of lymphoma, however each 
entity studied separately, have so far been recognised22,23. 
There is also a notion that the higher cumulative level of 
infl ammation, in patients with RA, in comparison to those 
with SpA, is probably responsible for the higher observed 
risk of lymphoma, in the former group19. A logical infer-
ence arising from these facts is that there must be some 
other relevant factors except infl ammation which may, in 
patients with SpA, direct pathogenetic mechanisms to-
wards lymphomagenesis. Based on the existent knowl-
edge, this extra contribution may come from the specifi c 
genetic background which in patients with SpA is marked 
with the presence of the HLA-B27 antigen. In this regard, 
the evidence suggests that patients with AS and the con-
comitant expression of this antigen are likely to be predis-
posed to more aggressive forms of haematological malig-
nancies, specifi cally of the lymphoid tissue origin24. 
Moreover, not only the status of being HLA-B27 positive, 
but also the level of this antigen expression, is likely to be 
important for the decision on whether clinical expression 
of AS will really occur25. Taken together, strong HLA-B27 
positivity, as responsible for fast progression of AS and 
early age at disease onset, might also, in these patients, 
be associated with the propensity of developing lymphoma 
in early adulthood age. This statement is likely to be sup-
ported by the evidence that factors responsible for the fast 
transfer from early SpA disease stage to the overt spine 
disease include male sex (known to be more strongly as-
sociated with the HLA-B27 antigen expression than fe-
male sex) and elevated infl ammation level, manifested 
with increased C-reactive protein (CRP)26. Recently pub-
lished case reports may be used to support this assump-
tion. These reports include the case of a 38-year-old man 
with 15 year long history of HLAB-27 positive AS and the 
naturally developed Hodgkin’s lymphoma27. When this 
strictly genetically engineered program, based on the 
HLA-B27 antigen expression, is lacking, some other con-
tributing factors, in patients with SpA, such as severe 
immunosuppression, developed for example after intensive 
anti-infl ammatory treatment, might be necessary to medi-
ate lymphoma development. This alternative scenario is 
likely to be described in another case report, presented 
with a 45-year old woman with the history of AS who re-
ceived TNF blocker etanercept and large amounts of glu-
cocorticoid immunosupressive therapies and was, not long 
after that, complicated with lymphoma28. In this regard, 
world knowledge on the association of chronic infl amma-
tory and rheumatic diseases with the subsequent lym-
phoma development has revealed some common risk fac-
tors, including prolonged disease course and increased 
disease severity. B-cell NHL, especially diffuse large B-
cell lymphoma, was found to be the most frequent type of 
lymphoproliferative disorders, in these patients. By infor-
mation integration, it was possible to realise that the ques-
tion of whether or not lymphoma will occur, and of which 
kind, is largely infl uenced by patient age and disease-
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specifi c mechanisms14,22,29. In this context, the method of 
case-based reports might be of signifi cant importance to 
learning on the time-dependent course of a disease and on 
complexity of the contextual factors, providing us with 
better understanding and the capability to deal with new 
antiinfl ammatory treatments.
In contrast to what has been described above as to be 
conventional AS/lymphoma phenotypes, we presented 
here the case of an older woman with late-life AS expres-
sion, on the basis of undifferentiated SpA, or reactive ar-
thritis, combined with abudantly developed degenerative 
changes of the spine and peripheral joints (the knees). This 
jointed condition could contribute a lot to the overal in-
fl ammation burden in this woman. Chronic latent infec-
tion, as indicated with ureaplasma positive cervical smear 
culture, could also give the contribution to both, pathogen-
esis of infl ammatory joint disease and increased systemic 
infl ammation. In addition to that, advanced age per se is 
a condition known to cause increased systemic infl amma-
tion, which has been proposed to account for many age-
dependent phenotypic changes30. On such background, 
persistent B-lymphocyte proliferation, mandatory to lym-
phoma formation, could easily take place. Namely, each of 
these mechanisms, including aging, increased systemic 
infl ammation and autoimune infl ammatory disease, even 
taken separately, can be the underlying mechanism of ab-
normal cells growth and impaired cell-cycle control, lead-
ing to the both, the immune system dysfunction and the 
development of lymphoproliferative disorders31–33. This can 
especially be a case when older age, as it is in this example, 
is combined with unfavorable disease context, including 
insulin resistance, due to the overweight and long-lasting 
hypertension34. Insulin resistance state, in our report, is 
further implicated by endometrial hypertrophy and the 
episode of vaginal bleeding. When wider pathophysiologic 
background, shared between close family members, are 
added, then cardiovascular diseases (CVDs) can also be 
taken into account as a part of this complex pathogenetic 
background (history of CV death in a sister). In this re-
gard, it is known that in patients with AS, there is higher 
risk for CVDs, independently on whether they are HLA-
B27 positive, or not35,36.
Taken together, in our example, it is likely that HLA-
B27 negativity, combined with female gender and older age 
at disease onset, has allowed for many environmental and 
disease-specifi c factors to gather over time and to modify 
the primary genetic background, which was not propen-
sive enough to allow the early SpA development. Exactly 
advanced age, due to the late SpA onset, by masking the 
course of the disease, could allow lymphoma to develop. 
By revealing these multiple pathogenetic layers, we could 
improve our capabilities to navigate biologic therapy in the 
future, by targeting both, the course of AS and lymphoid 
tissue malignant transformation37. By fi ne tuning this 
therapy, we would be also able to mitigate the hazardous 
effect of the concomitant CV risk factors38.
We selected this case for presentation for one more rea-
son – to show that an infl ammatory niche, in addition to 
the systemic factors, might also be necessary for lympho-
ma development. This is indicated by the paravertebral 
location of the lymphoid tumor, indicating its origin in the 
local lymph nodes, placed in the close proximity of the 
spine structures. This location might have been important 
for the reason of supply of proliferated B-cells, within ger-
minal centers, with chronic antigenic load, in the form of 
degraded products of the infl ammatory affected spine 
structures, which is necessary for B-cells oncogenic trans-
formation14,39–42. This location could also provide an ap-
propriate microenvironment for the tumor growth, due to 
the large amounts of proinfl ammatory cytokines and 
other important mediators42,43. The requirement for the 
local infl ammatory niche, for lymphoma development, in 
patients with SpA, can also be recognised in some other 
published reports, including an example of an older man 
with primary knee synovial NHL, associated with long-
standing AS and the knee infl ammation44.
It seems, based on this analysis, that early detection of 
subjects at increased risk for the development of lympho-
ma, in patients with SpA, would require biomarkers de-
velopment and predictive modeling, to support our efforts 
to target anti-infl ammatory treatment on time, to prevent 
clinical expression of both, overt spinal disease and its 
hazardous complications. In order to achieve this goal, 
case-based reports can be a valuable method, by providing 
us with necessary understanding of the complex pathoge-
netic background of SpA related issues and factors infl u-
encing changes through time. In case of this achievement, 
reports as it is this one, would only be a lesson learnt from 
the past time.
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KOINCIDENCIJA IZMEĐU HLA-B27 NEGATIVNOG SPONDILOARTRITISA I PARAVERTEBRALNE 
LOKALIZACIJE NON-HODGKIN-OVOG LIMFOMA – LEKCIJA KOJU BI TREBALO NAUČITI IZ 
PROŠLOSTI
S A Ž E T A K
Prikazali smo slučaj 71-godišnje žene s progresivnim bolom u križima i neurološkim simptomima donjih ekstremite-
ta, čiju je pozadinu činila koegzistencija spondiloartritisa (SpA) i ne-Hodgkin-ova limfoma paravertebralne lokalizacije. 
Taj slučaj opisuje situaciju gdje je SpA s minimalnim promjenama na sakroilijačnim zglobovima ipak doveo do razvija 
uznapredovalog oblika aksijalnog SpA. Ta situacija je uključivala nediferencirani ili reaktivni SpA, kao i neuobičajeni 
klinički kontekst predstavljen kasnim početkom bolesti, starijom dobi, ženskim spolom i odsustvom nasljedne predis-
pozicije bolesti. Takva kombinacija ko-morbiditetnih čimbenika je bila pogodna da omogući okolišnim i za bolest 
specifi čnim čimbenicima da se nakupljaju kroz vrijeme i da, modifi cirajući primarnu, slabo penetrirajuću genetsku 
podlogu, dovedu do razvoja limfoma. S boljim razumijevanjem patofi ziološke dinamike bolesti, poboljšat ćemo i našu 
sposobnost da specifi čno usmjeravamo biološku terapiju u budućnosti, da bi spriječili razvoj, kako uznapredovalog oblika 
SpA, tako i limfoproliferativne bolesti.
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